Shares of Sequenom rose 11 percent for the four-day trading period ended Tuesday. Almost all of that increase came after Oppenheimer analyst Sean Lavin on Monday initiated the stock with a “buy” rating. Lavin put an $8 price target on Sequenom’s shares, which were trading at $5.20 on Wednesday afternoon.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.